Dainippon Sumitomo Pharma Co., Ltd.

Taisho Pharmaceutical Co., Ltd.

Japan Energy Corporation

Meiji Seika Kaisha, Ltd.

Meiji Seika Pharma Co., Ltd.

Haruhisa Ogita

Satoshi Yoshida

Yoshiaki Isobe

Haruo Takaku

Masanori Tobe

Ayumu Kurimoto

Tetsuhiro Ogino

Masato Kashimura

Hajime Kawakami

Eiki Shitara

Tomohiro Sugimoto

Tomoaki Miura

Hitoshi Fujita

Kenichi Kanemoto

Madoka Kawamura

Kanako Yamamoto

Naoki Sasamoto

Jun Kurosaka

Hiroyuki Matsui

Masato Hayashi

Toshifumi Asaka

Kiyoshi Takayama

Keiji Tamura

Dai Kubota

Kou Kumura

Yasunobu Ushiki

Ken Chikauchi

Akira Manaka

Nobuyoshi Chiba

Tomohiro Ozawa

Hideyuki Tomizawa

Kohsaku Hirota

Harumi Satoh

H c/o Sumitomo Pharmaceuticals COLTD Fujita

Y c/o Sumitomo Pharmaceuticals Co Ltd Isobe

A c/o Sumitomo Pharmaceuticals COLTD Kurimoto

H c/o Sumitomo Pharmaceuticals COLTD Takaku

T c/o Sumitomo Pharmaceuticals COLTD Ogino

M c/o Sumitomo Pharmaceuticals Co Ltd Tobe

A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas). 

C-4&#x2033; position substituted macrolide derivative

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; Xrepresents oxygen, sulfur, NR(Rrepresents hydrogen or alkyl), or a single bond; Yrepresents a single bond, alkylene, etc.; Yrepresents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Qand Qrepresents &#x2014;COOR(wherein Rrepresents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

Adenine compound and use thereof

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

Macrolide derivatives

[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

10a-Azalide compound

This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR(wherein Rrepresents a hydrogen atom or Calkyl) or the like; Rrepresents substituted or unsubstituted alkyl or the like; Rrepresents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.

Adenine derivatives

Type 2 helper T cell-selective immune response suppressors

Purine derivative

Growing community of inventors

Saitama, Japan

Haruhisa Ogita